Incretin-based therapy: renal effects

Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic ki...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anton Ivanovich Korbut, Vadim Valerievich Klimontov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	diabetes diabetic nephropathy glucagon-like peptide-1 dipeptidyl peptidase-4 incretin-based therapy Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/5c2fe686f9b64d1a9647f4b4cad14b69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c2fe686f9b64d1a9647f4b4cad14b69
record_format	dspace
spelling	oai:doaj.org-article:5c2fe686f9b64d1a9647f4b4cad14b692021-11-14T09:00:20ZIncretin-based therapy: renal effects2072-03512072-037810.14341/DM7727https://doaj.org/article/5c2fe686f9b64d1a9647f4b4cad14b692016-01-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7727https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic kidneys. Growing evidence indicates that the kidney is one of the loci of the effects and degradation of GLP-1. The potency of the effects of GLP-1 in diabetic kidneys can be reduced by decrease in GLP-1 receptor expression or enhancement of GLP-1 degradation. In experimental models of diabetic nephropathy and non-diabetic renal injury, GLP-1 analogues and DPP-4 inhibitors slow the development of kidney fibrosis and prevent the decline of kidney function. The mechanisms of protective effect include hyperglycaemia reduction, enhancement of sodium excretion, suppression of inflammatory and fibrogenic signalling pathways, reduction of oxidative stress and apoptosis in the kidneys. In clinical studies, the urinary albumin excretion reduction rate while using the GLP-1 analogue and DPP-4 inhibitor treatment was demonstrated in patients with type 2 diabetes. Long-term impact of these agents on renal function in diabetes needs further investigations.Anton Ivanovich KorbutVadim Valerievich KlimontovEndocrinology Research Centrearticlediabetesdiabetic nephropathyglucagon-like peptide-1dipeptidyl peptidase-4incretin-based therapyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 1, Pp 53-63 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes diabetic nephropathy glucagon-like peptide-1 dipeptidyl peptidase-4 incretin-based therapy Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes diabetic nephropathy glucagon-like peptide-1 dipeptidyl peptidase-4 incretin-based therapy Nutritional diseases. Deficiency diseases RC620-627 Anton Ivanovich Korbut Vadim Valerievich Klimontov Incretin-based therapy: renal effects
description	Glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors are new classes of hypoglycemic agents with numerous pleiotropic effects. The review summarises data about the influence of GLP-1 analogues and DPP-4 inhibitors on structural and functional changes in diabetic kidneys. Growing evidence indicates that the kidney is one of the loci of the effects and degradation of GLP-1. The potency of the effects of GLP-1 in diabetic kidneys can be reduced by decrease in GLP-1 receptor expression or enhancement of GLP-1 degradation. In experimental models of diabetic nephropathy and non-diabetic renal injury, GLP-1 analogues and DPP-4 inhibitors slow the development of kidney fibrosis and prevent the decline of kidney function. The mechanisms of protective effect include hyperglycaemia reduction, enhancement of sodium excretion, suppression of inflammatory and fibrogenic signalling pathways, reduction of oxidative stress and apoptosis in the kidneys. In clinical studies, the urinary albumin excretion reduction rate while using the GLP-1 analogue and DPP-4 inhibitor treatment was demonstrated in patients with type 2 diabetes. Long-term impact of these agents on renal function in diabetes needs further investigations.
format	article
author	Anton Ivanovich Korbut Vadim Valerievich Klimontov
author_facet	Anton Ivanovich Korbut Vadim Valerievich Klimontov
author_sort	Anton Ivanovich Korbut
title	Incretin-based therapy: renal effects
title_short	Incretin-based therapy: renal effects
title_full	Incretin-based therapy: renal effects
title_fullStr	Incretin-based therapy: renal effects
title_full_unstemmed	Incretin-based therapy: renal effects
title_sort	incretin-based therapy: renal effects
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/5c2fe686f9b64d1a9647f4b4cad14b69
work_keys_str_mv	AT antonivanovichkorbut incretinbasedtherapyrenaleffects AT vadimvalerievichklimontov incretinbasedtherapyrenaleffects
_version_	1718429529628737536

Incretin-based therapy: renal effects

Ejemplares similares